chemXplore tracks 61 projects in Mexico, of which 43 are active.
Of the active ones, 19 expansion, 17 new construction and 7 revamp / retrofit.
25 active projects carry no start-up date yet. The dates themselves, per project, are for subscribers.
Operating EBITDA rose 14.5% on a constant-currency basis, while the gross margin narrowed as sourcing costs increased.
EBITDA up 34% YoY to $2.0bn; adjusted EPS $1.15; net debt rose to $10.3bn while liquidity stays $8.7bn; strategic projects raise EBITDA potential by ~$1.8bn.
Upgrades at three sites add lines, new acrylics capacity and advanced controls to boost local production for automotive, battery and industrial markets.
Proforma gearing at a historic low of 9% and adjusted CFFO lifted to €16.5bn; underlying E&P output +7% to 1.83 mln boe/d. Strategic deals include Junin 5 relaunch and asset monetisations.
Adds specialty alumina grades for ceramics, polishing and other industrial uses across Mexico and Latin America (ex‑Brazil), extending an existing U.S. collaboration.
Once‑daily oral GLP‑1 cut MACE vs insulin glargine, lowered A1C by 1.6% at 52 weeks and produced mean weight loss of 8.1 kg with durable effects to 104 weeks.
EU launches anti-dumping probe after PVC imports doubled in 12 months; industry urges faster provisional measures, safeguards and more DG Trade resources to protect European production.
An indirect, covariate‑adjusted comparison of SURMOUNT‑1 and STEP UP data shows larger mean and categorical weight‑loss benefits with tirzepatide 10 mg and 15 mg at 72 weeks.
FDA clears once‑weekly basal insulin that reduces injection frequency vs daily therapy; Phase 3 QWINT trials in >3,400 adults showed non‑inferior A1C vs glargine and degludec.
Cryoinfra 50,000 Nm³/h air separation cold box and atmospheric storage tank installation in Mexico reaches intermediate handover.
active / all projects
The 10 with the most active projects, of 13 parks.